Findings

What do systematic reviews say?

8 questions · 10 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 40%GRADE not reported 0 · 0%Very low 2 · 20%Low 4 · 40%Moderate 0 · 0%High 0 · 0%

Infliximab 5 mg/kg vs purine analogues

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.7 [0.46, 1.06]
2 studies · 355 participants
Low

Infliximab 5 mg/kg vs infliximab 10 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.03 [0.07, 15.79]
1 study · 63 participants
Very low

Infliximab 5 mg/kg vs infliximab 20 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 1.26 [0.7, 2.25]
1 study · 220 participants
Low

Infliximab 10 mg/kg vs infliximab 20 mg/kg

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Infliximab 5–10 mg/kg vs placebo

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

2 findings from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 2.5 [0.12, 50.54]
1 study · 94 participants
Very low

Infliximab 5 mg/kg and purine analogues vs purine analogues

Withdrawals due to adverse events · Patients with active Crohn's disease

Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).

1 finding from 1 review

Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes only
RR 0.87 [0.63, 1.21]
4 studies · 603 participants
Low

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review

Natalizumab for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.18 [0.01, 4.18]
1 study · 79 participants
Low